Iproteos: Science at the service of patients
Innovaspain.com has dedicated an article to the research undertaken by Iproteos, a company specialized in the discovery of drugs for diseases of the nervous system. This spin-off company of IRB Barcelona has demonstrated the effectiveness of a novel compound, IPR-19, to reverse the cognitive deficit associated with schizophrenia in mouse models. At present, this peptide is in the preclinical phase.
Link to Innovaspain.com
Related content
News
Iproteos, one of the 5 spin-offs launched by IRB Barcelona, focuses on the development of third-generation drugs for diseases such as schizophrenia, epilepsy, and atherosclerosis.
Its proprietary technology allows faster research processes to identify new drugs and produce novel molecules.
The new company Accure Therapeutics starts up with €7.6 M of investment, which will allow the development of its product portfolio and the takeover of Iproteos and Bionure.
Expansión, El Periódico de Catalunya and Diario de Córdoba, among other media, have published articles about the biotechnologist Iproteos, a company created in 2011 by the scientists Teresa Tarragó and Ernest Giralt and based on the transfer of a technology developed atIRB Barcelona and the University of Barcelona (UB). The company has launched a project to develop a therapeutic strategy, designed by IBEC, to treat solid tumours, which account for 90-95% of cancer cases.
The “Dinero” supplement of the newspaper La Vanguardia has interviewed Roger Gomis, ICREA researcher at IRB Barcelona, about Inbiomotion, a spin-off from the institute and ICREA. This company, which came about from biomedical research and an entrepreneurial spirit, develops and commercialises a diagnostic test that allows the identification of those breast cancer patients most likely to develop bone metastasis.
